Peripheral artery disease, lower limb revascularization, and amputation in diabetes patients with and without coronary artery disease: a cohort study from the Western Denmark Heart Registry

Kevin Kris Warnakula Olesen,1 Christine Gyldenkerne,1 Troels Thim,1 Reimar Wernich Thomsen,2 Michael Maeng1

ABSTRACT

Introduction Patients with diabetes have increased risk of lower limb revascularization and amputation due to higher risk of peripheral artery disease (PAD) and peripheral neuropathy. The additive effect of coronary artery disease (CAD) is less clear. We examined the risk of PAD, lower limb revascularization, and amputation in diabetes and non-diabetes patients with and without CAD in patients examined by coronary angiography (CAG).

Research design and methods We included all patients undergoing CAG between 2003 and 2016 in Western Denmark. Patients with previous CAD, PAD, lower limb revascularization, or amputation were excluded. Patients were stratified by diabetes and CAD status and followed for a maximum of 10 years. Outcomes were PAD, lower limb revascularization, and amputation. We estimated 10-year cumulative incidences and adjusted HRs (aHRs) using patients neither diabetes nor CAD as reference.

Results A total of 118,787 patients were included, of whom 41,878 (35%) had neither diabetes nor CAD, 57,355 (5%) had diabetes alone, 59,427 (50%) had CAD alone, and 11,747 (10%) had both diabetes and CAD. Median follow-up was 6.9 years. Diabetes patients without CAD had higher risk of PAD (3.5%, aHR 1.73, 95% CI 1.51 to 1.97), lower limb revascularization (1.6%, aHR 1.55, 95% CI 1.16 to 2.05), and lower limb amputation (2.4%, aHR 1.51, 95% CI 1.09 to 2.23) compared with patients with neither diabetes nor CAD. CAD was associated with 2.5-fold and 1.8-fold higher risk of PAD and amputation, respectively, among patients without diabetes, and associated with 3.9-fold and 9.5-fold higher risk of PAD and lower limb amputation among patients with diabetes.

Conclusions Despite absence of obstructive CAD, patients with diabetes remained at higher risk of PAD, lower limb revascularization, and lower limb amputation. Diabetes was more strongly associated with amputation than CAD, but CAD exacerbated the risks of PAD, revascularization, and amputation in patients with diabetes.

What is already known about this subject?

► Patients with diabetes have increased risk of lower limb amputation due to higher risk of peripheral artery disease and peripheral neuropathy. The role of concomitant coronary artery disease (CAD) is unclear.

What are the new findings?

► Patients with diabetes are at higher risk of lower limb amputation despite absence of CAD.
► However, CAD significantly exacerbates amputation risk among patients with diabetes, especially in patients with multivessel CAD.
► Diabetes patients without CAD were more likely to undergo distal amputations, rather than proximal amputations, which were associated with CAD.

How might these results change the focus of research or clinical practice?

► Continued screening and treatment of macrovascular and microvascular disease is necessary in all patients with diabetes to reduce the risk of amputation. However, patients with diabetes and CAD may require additional screening, management, and treatment of peripheral artery disease and microvascular disease to reduce the risk of lower limb amputation. This, however, needs to be explored in a randomized setting.

INTRODUCTION

Diabetes is associated with a higher risk of atherosclerotic cardiovascular disease including ischemic stroke, coronary artery disease (CAD), and peripheral artery disease (PAD).1 2 Patients with diabetes also have an increased risk of microvascular disease, including peripheral neuropathy, which can...
cause foot ulcers. Poor glycemic control, type of diabetes, previous lower limb revascularization, hypertension, and high level of comorbidity are all associated with increased risk of amputation in patients with diabetes. Atherosclerosis in one vascular bed is often associated with presence or development of atherosclerosis in other vascular beds. Considering the combination of increased atherothrombotic risk and the risk of microvascular disease, patients with diabetes have a higher risk of lower limb ischemia and amputation. The absence of obstructive CAD is associated with a low risk of myocardial infarction and an intermediate risk of ischemic stroke in patients with diabetes. However, does the absence of obstructive CAD ensure a low risk of PAD, lower limb revascularization, and amputation in patients with diabetes?

We conducted a cohort study of diabetes and non-diabetes patients with and without obstructive CAD to estimate the risk of PAD, lower limb revascularization, and lower limb amputation. We hypothesized that the absence of obstructive CAD by coronary angiography (CAG) would be associated with low risks of PAD, lower limb revascularization, and lower limb amputation in both diabetes and non-diabetes patients.

METHODS

Setting
All Danish residents are assigned a unique 10-digit identifier at birth or immigration. This identifier is used throughout every national and regional registry, thus allowing accurate cross-linkage of data between registries. The Civil Registration System contains information on vital status of every resident in Denmark, hereby reducing loss to follow-up (<0.3%). The Danish National Patients Registry records every discharge diagnoses for in-hospital admission and visits to outpatient clinics in national Danish healthcare system. The Danish National Prescription Registry contains information on every dispensed prescription from a Danish pharmacy since 1994. The Western Denmark Heart Registry has registered every cardiac procedure in Western Denmark since 1999, and it contains detailed patient-related and procedural information that includes the presence and extent of CAD.

Patient selection
We included all patients examined by CAG from 1 January 2003 to 31 December 2016 (figure 1). We excluded patients aged <18 years and patients with previous history of myocardial infarction (MI), percutaneous coronary intervention, or coronary artery bypass grafting (CABG) prior to CAG date to identify patients with a first-time diagnosis of CAD. We also excluded patients diagnosed with PAD, previous lower revascularization, or amputation before start of follow-up. Patients with missing CAD status were not included, as well as patients classified as ‘no CAD’ but were revascularized within 30 days of CAG.

Lastly, patients who either died or emigrated <30 days after CAG were excluded.

Diabetes
Diabetes was defined as at least one of the following: (1) dietary treatment for diabetes, oral diabetes treatment, or receiving insulin treatment (±oral diabetes treatment) recorded in the Western Denmark Heart Registry, (2) a previous diabetes diagnosis registered in the Danish National Patient Registry before start of follow-up, or (3) redeeming ≥1 prescription(s) of insulin or non-insulin diabetes medication 6 months before or 30 days after CAG.

Coronary artery disease
CAD was defined as ≥1 obstructive stenoses (≥50% lumen narrowing) or non-obstructive stenosis in ≥2 coronary vessels by CAG according to the Western Denmark Heart Registry.

Outcomes
PAD was defined as a primary or secondary discharge diagnoses of PAD during hospitalization or visit to outpatient clinic (online supplemental table S1). Lower limb revascularization was defined as thrombectomy, percutaneous transluminal angioplasty, or arterial bypass surgery distal from the infrarenal aorta. Lower limb amputation was defined as an amputation from hip down. The level of the amputation was evaluated as separate outcomes (hip/femur amputation, knee/lower leg amputation, and ankle/foot/toe amputation).

Statistical analysis
Follow-up started 30 days after CAG to allow for any CAG-related changes in comorbidities and medications to be registered. Follow-up continued until outcome, emigration, death, end of follow-up (31 December 2018) with a maximum of 10 years of follow-up. Events occurring more than 10 years after start of follow-up were censored. Event rates per 100 person-years were estimated. The 10-year cumulative incidence proportions accounting for the competing risk of all-cause death were calculated. Crude and adjusted HRs (aHRs) were estimated using Cox proportional regression analysis and non-diabetes patients without CAD as reference. The central assumption of proportional hazards was evaluated by log-log plots and found to be satisfied. HR were adjusted for age, sex, hypertension, microvascular disease, active smoking, categorized body mass index (<18.5 kg/m², 18.5–24.9 kg/m², 25–29.9 kg/m², ≥30 kg/m²), oral anticoagulant treatment (vitamin K antagonists or direct oral anticoagulants), antiplatelet treatment (aspirin and/or adenosine diphosphate (ADP) inhibitors), and statin treatment. A total of 19.3% of patients had missing data of either smoking (9.9%) and/or body mass index (14.4%). Missing data were handled through multiple imputation using chained equations, imputing 20 datasets.
Cardiovascular and metabolic risk

Diabetes subgroup analysis
We performed stratified analysis of patients with diabetes by: (1) extent of CAD (0 vessel disease (VD), 1 VD, 2 VD, 3 VD, and diffuse VD), (2) type of diabetes treatment, and (3) duration of diabetes (0–4 years, 5–9 years, and ≥10 years). We tested for trend between extent of CAD and each outcomes in patients with diabetes.

Amputation distribution
We counted the distribution of type of amputation (hip/femur, knee/lower leg, and ankle/foot/toe), and tested the hypothesis of no difference in distribution of type of amputation using Pearson’s $\chi^2$ test.

RESULTS
We included 118 787 patients, of whom 41 878 (35%) had neither diabetes nor CAD, 5735 (5%) had diabetes alone, 59 427 (50%) had CAD alone, and 11 747 (10%) had both diabetes and CAD (figure 1). Median follow-up was 6.9 years (IQR 4.0–10.0).

Regardless of presence or absence of diabetes, patients with CAD were older, more often men, and more often treated with antiplatelet agents and statin (table 1 and online supplemental table S2).

Regardless of CAD, patients with diabetes more often had hypertension, heart failure, previous ischemic stroke, and microvascular disease. Type of diabetes treatment was overall similar between diabetes patients with and without CAD. However, insulin and sulfonylureas were used more frequently among diabetes patients with CAD.

Compared with patients with neither diabetes nor CAD, the risk of PAD and lower limb revascularization was highest in patients who had both diabetes and CAD, followed by patients with CAD alone and patients with diabetes alone (table 2).
Cardiovascular and metabolic risk

Diabetes alone patients had a lower risk of PAD compared with CAD alone patients (figure 2). However, PAD risk did seem to more progressively increase during follow-up among diabetes alone patients reaching a comparable 10-year risk as patients with CAD alone (diabetes alone: 6.9% vs CAD alone: 7.9%). Patients with both diabetes and CAD had an almost 10-fold increased risk of lower limb amputation when compared with patients with neither diabetes nor CAD (3.8% vs 0.3%, aHR 9.49, 95% CI 7.27 to 12.39). Of note, diabetes alone

Table 1  Baseline characteristics in patients with and without diabetes by coronary artery status

<table>
<thead>
<tr>
<th></th>
<th>No DM, no CAD (n=41 878)</th>
<th>DM, no CAD (n=5735)</th>
<th>No DM, CAD (n=59 427)</th>
<th>DM, CAD (n=11 747)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
</tr>
<tr>
<td>Median age (IQR)</td>
<td>61 years (52–69)</td>
<td>49.8</td>
<td>62 years (53–70)</td>
<td>48.4</td>
</tr>
<tr>
<td>Female</td>
<td>20 873</td>
<td>49.8</td>
<td>2777</td>
<td>48.4</td>
</tr>
<tr>
<td>Active smoker*</td>
<td>20 873</td>
<td>21.2</td>
<td>1080</td>
<td>18.8</td>
</tr>
<tr>
<td>Mean body mass index* (±SD)</td>
<td>26.9 kg/m²±5.1</td>
<td>30.8 kg/m²±6.5</td>
<td>26.8 kg/m²±4.4</td>
<td>29.4 kg/m²±5.3</td>
</tr>
<tr>
<td>Mean eGFR* (±SD)</td>
<td>89 mL/min (25.6)</td>
<td>92 mL/min (32.2)</td>
<td>86 mL/min (25.1)</td>
<td>86 mL/min (30.2)</td>
</tr>
<tr>
<td>Mean systolic BP*</td>
<td>137 mmHg (22)</td>
<td>140 mmHg (22)</td>
<td>139 mmHg (23)</td>
<td>141 mmHg (23)</td>
</tr>
<tr>
<td>Mean diastolic BP*</td>
<td>78 mmHg (13)</td>
<td>78 mmHg (13)</td>
<td>77 mmHg (13)</td>
<td></td>
</tr>
<tr>
<td>Median DM treatment duration, (IQR)</td>
<td>4.0 years (0.5–9.4)</td>
<td></td>
<td>4.8 year (0.6–10.7)</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>20 157</td>
<td>48.1</td>
<td>4450</td>
<td>77.6</td>
</tr>
<tr>
<td>Heart failure</td>
<td>6246</td>
<td>14.9</td>
<td>1113</td>
<td>19.4</td>
</tr>
<tr>
<td>Ischemic stroke</td>
<td>594</td>
<td>1.4</td>
<td>200</td>
<td>3.5</td>
</tr>
<tr>
<td>Transient ischemic attack</td>
<td>966</td>
<td>2.3</td>
<td>137</td>
<td>2.4</td>
</tr>
<tr>
<td>Carotid stenosis</td>
<td>30</td>
<td>0.1</td>
<td>4</td>
<td>0.1</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>6588</td>
<td>15.7</td>
<td>1043</td>
<td>18.2</td>
</tr>
<tr>
<td>Nephropathy</td>
<td>49</td>
<td>0.1</td>
<td>376</td>
<td>6.6</td>
</tr>
<tr>
<td>Retinopathy</td>
<td>31</td>
<td>0.1</td>
<td>808</td>
<td>14.1</td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
<td>81</td>
<td>0.2</td>
<td>275</td>
<td>4.8</td>
</tr>
<tr>
<td>Comedication</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>21 223</td>
<td>50.7</td>
<td>3553</td>
<td>62.0</td>
</tr>
<tr>
<td>ADP inhibitor</td>
<td>2289</td>
<td>5.5</td>
<td>320</td>
<td>5.6</td>
</tr>
<tr>
<td>Vitamin K antagonist</td>
<td>5638</td>
<td>13.2</td>
<td>882</td>
<td>15.4</td>
</tr>
<tr>
<td>Direct oral anticoagulants</td>
<td>1030</td>
<td>2.5</td>
<td>182</td>
<td>3.2</td>
</tr>
<tr>
<td>Statin</td>
<td>17 543</td>
<td>41.9</td>
<td>4149</td>
<td>72.3</td>
</tr>
<tr>
<td>Insulin</td>
<td>0</td>
<td>0.0</td>
<td>1580</td>
<td>27.6</td>
</tr>
<tr>
<td>Non-insulin</td>
<td>0</td>
<td>0.0</td>
<td>3672</td>
<td>64.0</td>
</tr>
<tr>
<td>Metformin</td>
<td>3167</td>
<td>55.2</td>
<td>6480</td>
<td>55.2</td>
</tr>
<tr>
<td>Sulfonylureas</td>
<td>1127</td>
<td>19.7</td>
<td>2769</td>
<td>23.6</td>
</tr>
<tr>
<td>DPP-4 inhibitor</td>
<td>344</td>
<td>6.0</td>
<td>681</td>
<td>5.8</td>
</tr>
<tr>
<td>GLP-1 analogs</td>
<td>243</td>
<td>4.2</td>
<td>435</td>
<td>3.7</td>
</tr>
<tr>
<td>SGLT-2 inhibitors</td>
<td>29</td>
<td>0.5</td>
<td>73</td>
<td>0.6</td>
</tr>
<tr>
<td>Glitazones</td>
<td>42</td>
<td>0.7</td>
<td>100</td>
<td>0.9</td>
</tr>
<tr>
<td>Repaglinide</td>
<td>22</td>
<td>0.4</td>
<td>44</td>
<td>0.4</td>
</tr>
<tr>
<td>Acarbose</td>
<td>9</td>
<td>0.2</td>
<td>28</td>
<td>0.2</td>
</tr>
</tbody>
</table>

*Missing values: smoking (9.9%); BMI (14.3%), eGFR (26.4%), and blood pressure (13.3%).
ADP, adenosine diphosphate; BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; DM, diabetes mellitus; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; GLP-1, glucagon like peptide-1; SGLT-2, sodium–glucose cotransporter-2.
Cardiovascular and metabolic risk

(2.4%, aHR 5.51, 95% CI 4.09 to 7.43) was also associated with an increased risk of lower limb amputation, which was much higher than for patients with CAD alone (0.6%, aHR 2.02, 95% CI 1.57 to 2.60) compared with patients with neither diabetes nor CAD. Risks of PAD, lower limb revascularization, and amputation increased by extent of CAD in patients with diabetes (ptrend <0.0001, figure 3, online supplemental table S3). Insulin-treated patients had the highest risks of PAD, revascularization, and amputation (figure 3, online supplemental table S4). Duration of diabetes was also associated risk of PAD and amputation but not revascularization (figure 3, online supplemental table S5). Diabetes patients without CAD more often had distal lower limb amputations (ankle/foot/toe), while non-diabetes patients with CAD more often underwent proximal amputations (hip/femur) (online supplemental figure S1). The distributions of type of amputation differed significantly (p<0.001).

**DISCUSSION**

The main findings of the study were that diabetes still infers an increased risk of PAD and lower limb amputation despite the absence of obstructive CAD. Diabetes was
Cardiovascular and metabolic risk

associated with a higher risk of lower limb amputation compared with CAD, but the level of amputation differed between the two exposures. Furthermore, CAD was associated with an incremental risk of PAD and amputation among patients with diabetes. Diabetes patients with obstructive multivessel CAD, receiving insulin treatment, or with a long duration of diabetes had the highest risk. Although CAD alone patients had higher risk of PAD and lower limb revascularization than those with diabetes alone, diabetes alone patients remained at much higher risk of lower limb amputation than those with CAD alone. Hence, in patients with diabetes, the absence of CAD reduced the risk of lower limb amputation from a 9.5-fold increase to a 5.5-fold increase but did not by any means eliminate their highly elevated risk. Among Danish patients with a high prevalence of lipid-lowering

![Figure 2](image1.png)

**Figure 2** Ten-year cumulative incidence of peripheral artery disease, lower limb revascularization, and lower limb amputation by diabetes and coronary status. CAD, coronary artery disease; DM, diabetes.

![Figure 3](image2.png)

**Figure 3** Risk of peripheral artery disease, lower limb revascularization, and lower limb amputation in diabetes patient by presence and extent of CAD, diabetes treatment, and duration of diabetes. CAD, coronary artery disease; IRR, incidence rate ratio; PAD, peripheral artery disease; VD, vessel disease.
and antithrombotic treatment, MI risk in diabetes alone patients is low and comparable with patients with neither diabetes nor CAD, while their risk of ischemic stroke was higher.\textsuperscript{27,28} Hence, the absence of CAD by CAG ensures a sustained low risk of MI in patients with diabetes but does not protect from other cardiovascular outcomes including ischemic stroke, PAD, and lower limb amputation. Although this may not be generalizable to countries outside Denmark, this nevertheless emphasizes the need for continued monitoring and treatment of macrovascular and microvascular disease in patients with diabetes, in particular diabetes patients with CAD.

Patients with diabetes had higher prevalence of microvascular disease, irrespective of CAD status. Patients with diabetes often develop microvascular complications causing visual impairment, loss of sensory function, kidney failure and so on.\textsuperscript{16–18} Foot ulcers and amputations are also more frequent among patients with diabetes due to a combination of PAD and peripheral neuropathy.\textsuperscript{1} Reduced pain sensitivity may postpone PAD diagnosis in diabetes patients with polyneuropathy.\textsuperscript{1} Furthermore, microvascular disease increases the risk of amputation independently of PAD.\textsuperscript{19} Diabetes patients with peripheral microvascular disease have a higher risk of disseminated macrovascular atherosclerotic disease in multiple organs, including CAD, PAD, and cerebrovascular disease.\textsuperscript{20} Moreover, diabetes is associated with coronary microvascular disease and subsequent risk of adverse ischemic events.\textsuperscript{21} Screening for microvascular disease is a central part of diabetes management, and foot evaluations are recommended to prevent development of ulcers and amputation.\textsuperscript{22} We found that diabetes was associated with a higher prevalence of microvascular disease, which may both reflect a true higher prevalence as well as surveillance bias caused by routine screening of patients with diabetes in the primary sector. This could, in part, explain the higher amputation risk among patients with diabetes. Diabetes alone was primarily associated with distal amputations, whereas CAD alone was associated with proximal amputations. However, even when adjusting for diagnosed microvascular disease, diabetes alone patients still had higher risk of amputation than CAD alone patients.

CAD was associated with an increased risk of developing PAD and having lower limb revascularization. The Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial found that microvascular disease increased the risk of PAD and amputation in patients with type 2 diabetes, while macrovascular disease (previous coronary heart disease or cerebrovascular disease) did not affect the risk of PAD or amputation.\textsuperscript{23} A recent Danish cohort stratified patients with and without diabetes by extent of CAD by angiography (n=116 491), and similarly found that CAD extent was associated with an increased risk of PAD in patients with diabetes 5 years after CAG, with significant interaction between diabetes and CAD extent (p\textsubscript{interaction}=0.042).\textsuperscript{24} Researchers did not examine lower limb revascularization or amputation. As a confirmation and extension of the Danish angiographic cohort,\textsuperscript{24} we report that the presence of CAD more than doubles the risk of PAD, lower limb revascularization, and lower limb amputation. Our cohort consists of routine clinical care patients undergoing CAG contrary to the ADVANCE trial that included a more selective group of patients with type 2 diabetes. Furthermore, macrovascular disease was associated with revascularization for PAD (HR 1.75, 95% CI 1.13 to 2.73) in the ADVANCE trial too.

More than 8 in 10 patients with CAD received treatment with aspirin. The remaining were almost all treated with oral anticoagulants. Similarly, almost 9 in 10 patients with CAD were in statin treatment. Antiplatelet monotherapy and statin treatment are recommended in patients with symptomatic PAD.\textsuperscript{25} Oral anticoagulants are currently not recommended in management of PAD. However, more recently low dose of rivaroxaban in combination with aspirin has been found to reduce cardiovascular risk, including major amputation (HR 0.50, 95% CI 0.41 to 0.60), in patients with stable CAD or PAD.\textsuperscript{26,27} Moreover, additional antithrombotic treatment, including low-dose rivaroxaban, should be considered in chronic coronary syndrome patients with diabetes and/or PAD according to European guidelines.\textsuperscript{28,29} However, it is unknown whether supplementary antithrombotic medication would reduce amputation risk in diabetes patients with CAD. Sodium-glucose cotransporter (SGLT)-2 inhibitors and glucagon-like peptide (GLP)-1 analogs reduce cardiovascular risk and improve glycemic control in diabetes patients with atherosclerotic cardiovascular disease.\textsuperscript{30–38} However, SGLT-2 treatment have either had no impact or have been associated with an increased risk of amputation.\textsuperscript{31,36–38} Among the GLP-1 analogs, liraglutide reduces the risk of amputation semaglutide reduce the risk of lower limb revascularization,\textsuperscript{31,37} while exanetide did not reduce amputation nor revascularization.\textsuperscript{29} Thus, class effects of GLP-1 analogs on lower limb revascularization and amputation is undetermined. None of the pivotal trials were powered to examine the effect of GLP-1 analogs on lower limb revascularization or amputation, and they only included diabetes patients with established atherosclerotic disease. The role of GLP-1 analogs in reducing amputation risk needs additional investigation in dedicated clinical trials, including examining their effect in diabetes patients without established cardiovascular disease.

Limitations

We did not have access to hemoglobin A1c in our dataset, and we cannot account for the effect of hyperglycemia in our study. However, we did find that amputation was associated with pseudoindicators of diabetes disease severity such as duration of diabetes and insulin treatment. The use of aspirin and statin was high in patients with CAD, and this may have reduced the relative risk of symptomatic PAD, lower limb intervention, and lower limb amputation. As such, we have likely underestimated the PAD
risk among this subgroup. Our study included symptomatic patients undergoing CAG and may not represent the risk in the general population. Obstructive CAD was defined by 50% stenosis, which no longer reflects the current guidelines. However, in recent years Danish interventional cardiologists have increasingly been using intravascular pressure measurements, such as fractional flow ratio and adenosine-free resting indices, to identify functionally limiting lesions during CAG in accordance with guidelines. Lastly, PAD diagnosis were identified based on hospital and outpatient clinic diagnoses, likely underestimating the true prevalence of PAD.

CONCLUSIONS

Patients with diabetes had a higher risk of PAD, lower limb revascularization, and lower limb amputation despite the absence of CAD by CAG. Diabetes alone was associated with a higher risk of amputation than CAD alone. Furthermore, CAD was associated with risk of PAD, lower limb revascularization, and lower limb amputation among patients with diabetes, and the risks depend on the CAD extent, type of diabetes treatment, and the duration of diabetes. This emphasizes the need for continued monitoring and treatment of macrovascular and microvascular disease of all patients with diabetes, in particular, diabetes patients with documented CAD. Clinical trials are needed to examine whether newer glucose-lowering medications, such as SGLT2 inhibitors and GLP-1 analogs, can effectively prevent lower limb amputations in patients with diabetes both with and without established coronary atherosclerosis.

Contributors
KKWO and MM conceptualized and designed the study. KKWO performed data management, statistical analysis, and wrote first draft of the manuscript. GC, TT, RWT, and MM provided major revision of the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by the Research Unit, Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.

Competing interests
KKWO has received a speaking fee from Bayer. GC, TT, and RWT have nothing to declare. MM has received advisory board fees from Boehringer-Ingelheim, AstraZeneca, Novo Nordisk, BMS, Boston Scientific, and Bayer.

Patient consent for publication
Not required.

Ethics approval
The study was approved by a regional branch of the Danish Data Protection Agency (record no. 1-16-02-193-18). Registry-based studies do not require approval from ethics committees or informed consent from participants according to Danish regulation.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
No data are available. According to Danish data protection regulations, data cannot be made publicly available.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Kevin Kris Warnakula Olesen http://orcid.org/0000-0002-0560-3615
Cardiovascular and metabolic risk


